Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Obesity
NCT06780449Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in obesity, sponsored by Novo Nordisk. Started Feb 2025; status: active, not recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06780449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780449.